Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines

Anti-Cancer Drugs

Volumn 13, Issue 4, 2002, Pages 425-429

  Ekholm, Eeva ^a   Rantanen, Virpi ^a   Syvänen, Kari ^a   Jalonen, Jarmo ^a   Antila, Kari ^a   Salminen, Eeva ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Autonomic nervous system; Cardiotoxicity; Chemotherapy; Docetaxel; Heart rate variability

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN;

ADULT; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CARDIOTOXICITY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; DOSE RESPONSE; ELECTROCARDIOGRAM; FEMALE; HEART AUTOMATICITY; HEART RATE; HEART RATE VARIABILITY; HUMAN; INFECTION; PRIORITY JOURNAL; SKIN MANIFESTATION; SYSTOLE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CIRCADIAN RHYTHM; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0036241271     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200204000-00012     Document Type: Article

References (22)

1. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy
2. An expanding role for docetaxel
3. Taxol: The first of the taxanes, an important new class of antitumor agents
4. Cardiac disturbances during the administration of Taxol
5. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
6. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
7. Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer
8. Doxorubicin/taxane combinations: Cardiac toxicity and pharmacokinetics
9. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium
10. Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy
11. Impairment of heart rate variability during paclitaxel therapy
12. Differential effects of paclitaxel and derivatives on guinea pig isolated heart and papillary muscle
13. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: Autonomic versus echocardiographic variables
14. Hemodynamic regulation: Investigation by spectral analysis
15. New method for assessing cardiac parasympathetic activity using 24 hour electrocardiograms
16. Early left ventricular dysfunction elicits activation of sympathetic drive and attenuation of parasympathetic tone in the paced canine model of congestive heart failure
17. Detection of anthracycline-induced cardiotoxicity
18. Frequency domain measures of heart rate variability before the onset of nonsustained and sustained ventricular tachycardia in patients with coronary artery disease
19. Multicenter post-infarction research group: Decreased heart rate variability and its association with increased mortality after acute myocardial infarction
20. Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients
21. Paclitaxel changes sympathetic control of blood pressure
22. Absence of low-frequency variability of sympathetic nerve activity in severe heart failure